Inhibition of CXCL12/CXCR4 suppresses pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia

• Published in: Journal of receptors and signal transduction Vol. 35; no. 4; p. 329
• Main Authors: Wei, Liuping, Zhang, Bo, Cao, Weiwei, Xing, Hao, Yu, Xiufeng, Zhu, Daling
• Format: Journal Article
• Language: English
• Published: England 04.07.2015
• Subjects: Animals; Cell Cycle Checkpoints - physiology; Cell Hypoxia - physiology; Cell Proliferation - physiology; Cells, Cultured; Chemokine CXCL12 - antagonists & inhibitors; Chemokine CXCL12 - genetics; Chemokine CXCL12 - physiology; Humans; Hypertension, Pulmonary - pathology; Hypertension, Pulmonary - physiopathology; Male; Myocytes, Smooth Muscle - cytology; Myocytes, Smooth Muscle - metabolism; Phosphatidylinositol 3-Kinases - metabolism; Proto-Oncogene Proteins c-akt - metabolism; Pulmonary Artery - cytology; Pulmonary Artery - metabolism; Rats; Rats, Wistar; Receptors, CXCR4 - antagonists & inhibitors; Receptors, CXCR4 - genetics; Receptors, CXCR4 - physiology; RNA, Small Interfering - genetics; Signal Transduction; Vascular Remodeling - physiology; CXCR4; pulmonary arterial smooth muscle cell; CXCL12; proliferation; Cell cycle
• ISSN: 1532-4281
• DOI: 10.3109/10799893.2014.984308

Stromal cell-derived factor 1 (CXCL12) and its receptor CXC chemokine receptor 4 (CXCR4) are known to modulate hypoxia-induced pulmonary hypertension (PH) and vascular remodeling by mobilization and recruitment of progenitor cells to the pulmonary vasculature. However, little is known about CXCL12/CXCR4 regulating proliferation and cell cycle progression of pulmonary arterial smooth muscle cells (PASMCs). To determine whether CXCL12/CXCR4 regulates PASMC proliferation and the cell cycle, immunohistochemistry, Western blot, bromodeoxyuridine incorporation and cell cycle analysis were preformed in this study. Our results showed that CXCR4 was induced by hypoxia in pulmonary arteries and PASMCs of rats. Hypoxia-increased cell viability, DNA synthesis and proliferating cell nuclear antigen expression were blocked by administration of CXCR4 antagonist AMD3100, silencing CXCR4 or CXCL12. Furthermore, inhibition of CXCL12/CXCR4 suppressed cell cycle progression, decreased the number of cells in S+G2/M phase and attenuated the expression of proteins that regulate the cell cycle progression at these phases. In addition, PI3K/Akt signaling mediated CXCL12/CXCR4 regulating proliferation and cell cycle progression in PASMCs. Thus, these results indicate that blockade of CXCL12/CXCR4 inhibited PASMC proliferation and cell cycle progression in hypoxia-induced PH via PI3K/Akt signaling pathway.